Affimed NV
AFMD0.181USD
0.000
Close 09/19, 16:00（ET）Quotes delayed by 15 min
2.98MMarket Cap
LossP/E TTM
More Details of Affimed NV Company
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Company Info
Ticker SymbolAFMD
Company nameAffimed NV
IPO dateSep 12, 2014
CEOMr. Shawn M. Leland
Number of employees76
Security typeOrdinary Share
Fiscal year-endSep 12
AddressIm Neuenheimer Feld 582
CityHEIDELBERG
Stock exchangeBerne Stock Exchange
CountryGermany
Postal code69120
Phone49621560030
Websitehttps://www.affimed.com/
Ticker SymbolAFMD
IPO dateSep 12, 2014
CEOMr. Shawn M. Leland
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Wolfgang Fischer, Ph.D.
Dr. Wolfgang Fischer, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
145.54K
+34.45%
Ms. Denise Mueller
Ms. Denise Mueller
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
89.88K
+65.92%
Dr. Andreas Harstrick, M.D.
Dr. Andreas Harstrick, M.D.
Chief Medical Officer, Member of the Management Board
Chief Medical Officer, Member of the Management Board
76.04K
+88.54%
Dr. Mathieu Simon
Dr. Mathieu Simon
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
15.00K
+36.36%
Mr. Harry Welten
Mr. Harry Welten
Consulting Chief Financial Officer, Member of the Management Board
Consulting Chief Financial Officer, Member of the Management Board
15.00K
+36.36%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
14.00K
+16.67%
Ms. Uta Kemmerich-Keil
Ms. Uta Kemmerich-Keil
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
11.00K
+83.33%
Mr. Shawn M. Leland
Mr. Shawn M. Leland
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Bernhard R. M. Ehmer
Dr. Bernhard R. M. Ehmer
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Thomas Hecht, M.D.
Dr. Thomas Hecht, M.D.
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Wolfgang Fischer, Ph.D.
Dr. Wolfgang Fischer, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
145.54K
+34.45%
Ms. Denise Mueller
Ms. Denise Mueller
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
89.88K
+65.92%
Dr. Andreas Harstrick, M.D.
Dr. Andreas Harstrick, M.D.
Chief Medical Officer, Member of the Management Board
Chief Medical Officer, Member of the Management Board
76.04K
+88.54%
Dr. Mathieu Simon
Dr. Mathieu Simon
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
15.00K
+36.36%
Mr. Harry Welten
Mr. Harry Welten
Consulting Chief Financial Officer, Member of the Management Board
Consulting Chief Financial Officer, Member of the Management Board
15.00K
+36.36%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
14.00K
+16.67%
Revenue Breakdown
Currency: EURUpdated: Sun, Jul 6
Currency: EURUpdated: Sun, Jul 6
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessEUR
Name
Revenue
Proportion
Collaboration revenue
155.00K
0.00%
Service revenue
0.00
0.00%
By RegionEUR
Name
Revenue
Proportion
United States
155.00K
100.00%
Germany
0.00
0.00%
By Business
By Region
By BusinessEUR
Name
Revenue
Proportion
Collaboration revenue
155.00K
0.00%
Service revenue
0.00
0.00%
Shareholding Stats
Updated: Sat, Aug 23
Updated: Sat, Aug 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gilde Healthcare Partners B.V.
5.34%
Hoess (Adi Ph.D.)
2.10%
Fischer (Wolfgang)
0.96%
Mueller (Denise)
0.59%
Schottelius (Arndt)
0.55%
Other
90.47%
Shareholders
Shareholders
Proportion
Gilde Healthcare Partners B.V.
5.34%
Hoess (Adi Ph.D.)
2.10%
Fischer (Wolfgang)
0.96%
Mueller (Denise)
0.59%
Schottelius (Arndt)
0.55%
Other
90.47%
Shareholder Types
Shareholders
Proportion
Individual Investor
6.01%
Venture Capital
5.34%
Investment Advisor
0.08%
Other
88.58%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
144
3.74M
24.53%
-2.97M
2025Q1
194
5.44M
35.72%
-1.40M
2024Q4
223
4.37M
28.70%
-3.86M
2024Q3
244
6.36M
129.59%
-2.88M
2024Q2
256
6.34M
129.44%
-2.70M
2024Q1
265
6.05M
127.57%
-3.49M
2023Q4
282
6.20M
128.84%
-3.49M
2023Q3
294
6.99M
46.94%
-2.84M
2023Q2
315
7.55M
50.71%
-3.53M
2023Q1
317
8.81M
59.15%
-2.41M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gilde Healthcare Partners B.V.
812.50K
5.34%
+812.50K
--
Mar 15, 2024
Hoess (Adi Ph.D.)
319.68K
2.1%
+66.08K
+26.06%
Mar 15, 2024
Fischer (Wolfgang)
145.54K
0.96%
+37.29K
+34.45%
Mar 15, 2024
Mueller (Denise)
89.88K
0.59%
+35.71K
+65.92%
Mar 15, 2024
Schottelius (Arndt)
83.54K
0.55%
+35.71K
+74.65%
Mar 15, 2024
Harstrick (Andreas)
76.04K
0.5%
+35.71K
+88.54%
Mar 15, 2024
Smith (Angus W)
65.71K
0.43%
+13.29K
+25.36%
Mar 15, 2024
Hecht (Thomas M.D.)
38.54K
0.25%
+4.50K
+13.22%
Mar 15, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 06, 2024
Merger
10→1
Mar 06, 2024
Merger
10→1
Mar 06, 2024
Merger
10→1
Mar 06, 2024
Merger
10→1
Date
Type
Ratio
Mar 06, 2024
Merger
10→1
Mar 06, 2024
Merger
10→1
Mar 06, 2024
Merger
10→1
Mar 06, 2024
Merger
10→1
